Skye Bioscience Files Definitive Proxy Materials
Ticker: SKYE · Form: DEFA14A · Filed: Apr 16, 2026 · CIK: 0001516551
Sentiment: neutral
Topics: proxy-filing, corporate-action, pharmaceuticals
TL;DR
Skye Bioscience just dropped proxy materials, shareholders might vote soon.
AI Summary
Skye Bioscience, Inc. filed a Definitive Additional Materials (DEFA14A) on April 16, 2026. This filing includes proxy soliciting materials, likely related to upcoming shareholder votes or corporate actions. The company is based in San Diego, California, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates that Skye Bioscience is actively engaging with its shareholders regarding important corporate matters, which could impact the company's future direction and stock performance.
Risk Assessment
Risk Level: medium — DEFA14A filings often precede significant corporate events or shareholder votes, which can introduce uncertainty and volatility.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Filer of the DEFA14A
- 0001516551 (company) — CIK number for Skye Bioscience, Inc.
- 2026-04-16 (date) — Filing date of the DEFA14A
- San Diego, CA (location) — Location of Skye Bioscience, Inc.
FAQ
What is the purpose of this DEFA14A filing?
This filing is for Additional definitive proxy soliciting materials and Rule 14(a)(12) material, indicating it contains information for shareholders regarding a solicitation.
When was this filing submitted to the SEC?
The filing was submitted on April 16, 2026.
What is Skye Bioscience, Inc.'s CIK number?
Skye Bioscience, Inc.'s CIK number is 0001516551.
What industry does Skye Bioscience, Inc. operate in?
Skye Bioscience, Inc. operates in the Pharmaceutical Preparations sector (SIC code 2834).
Where is Skye Bioscience, Inc. located?
Skye Bioscience, Inc. is located at 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 16, 2026 regarding Skye Bioscience, Inc. (SKYE).